Needham & Co downgrades Celldex Therapeutics Inc. (Nasdaq ... as timelines are likely to be delayed and there is limited near-term newsflow to drive the stock valuation." Celldex Therapeutics, Inc., formerly AVANT …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company …
Oct 22 (Reuters) - Avant Immunotherapeutics Inc AVAN.O, which develops vaccines, said it agreed to merge with privately held Celldex Therapeutics Inc in a stock deal. Celldex and Avant shareholders will own 58 percent and 42 percent of …
symbol=ALNY On Tuesday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. recorded a …
Celldex expects that this cash plus anticipated proceeds from future sales of its common stock under the agreement with Cantor will be enough to fund working capital requirements and planned operations through 2018. However, the …
Yahoo!11mon
With this deal, Celldex is gaining a strong partner in the form of Bristol-Myers, a company with expertise in the field of immuno-oncology. Moreover, the deal terms look favorable – sharing of development costs and more importantly, the …